Russell Investments Group’s Lifecore Biomedical LFCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $58.8K | Buy |
11,199
+4,293
| +62% | +$21.6K | ﹤0.01% | 3586 |
|
|
2026
Q1 | $25.7K | Buy |
6,906
+3,950
| +134% | +$27.3K | ﹤0.01% | 3550 |
|
|
2025
Q4 | $24.2K | Sell |
2,956
-105
| -3% | -$777 | ﹤0.01% | 3559 |
|
|
2025
Q3 | $22.5K | Buy |
3,061
+2,803
| +1,086% | +$21.2K | ﹤0.01% | 3563 |
|
|
2025
Q2 | $2.1K | Buy |
+258
| New | +$1.74K | ﹤0.01% | 3585 |
|
|
2024
Q4 | – | Sell |
-84
| Closed | -$414 | – | 3755 |
|
|
2024
Q3 | $414 | Buy |
+84
| New | +$439 | ﹤0.01% | 3587 |
|
|
2023
Q2 | – | Sell |
-238,836
| Closed | -$902K | – | 3499 |
|
|
2023
Q1 | $902K | Hold |
238,836
| – | – | ﹤0.01% | 2025 |
|
|
2022
Q4 | $1.55M | Sell |
238,836
-52,934
| -18% | -$436K | ﹤0.01% | 1746 |
|
|
2022
Q3 | $2.59M | Sell |
291,770
-5,178
| -2% | -$52.7K | 0.01% | 1408 |
|
|
2022
Q2 | $2.96M | Buy |
296,948
+4,578
| +2% | +$45.3K | 0.01% | 1374 |
|
|
2022
Q1 | $3.38M | Sell |
292,370
-1,218
| -0.4% | -$13.6K | 0.01% | 1366 |
|
|
2021
Q4 | $3.26M | Sell |
293,588
-246,800
| -46% | -$2.4M | 0.01% | 1520 |
|
|
2021
Q3 | $4.98M | Sell |
540,388
-214,540
| -28% | -$2.33M | 0.01% | 1257 |
|
|
2021
Q2 | $8.49M | Sell |
754,928
-425,801
| -36% | -$4.91M | 0.01% | 1020 |
|
|
2021
Q1 | $12.5M | Sell |
1,180,729
-245,537
| -17% | -$2.76M | 0.02% | 822 |
|
|
2020
Q4 | $15.5M | Sell |
1,426,266
-1,392,984
| -49% | -$14.4M | 0.03% | 626 |
|
|
2020
Q3 | $27.4M | Sell |
2,819,250
-214,332
| -7% | -$2.04M | 0.06% | 362 |
|
|
2020
Q2 | $24.2M | Buy |
3,033,582
+225,553
| +8% | +$2.33M | 0.05% | 398 |
|
|
2020
Q1 | $24.4M | Sell |
2,808,029
-57,846
| -2% | -$602K | 0.06% | 329 |
|
|
2019
Q4 | $32.4M | Buy |
2,865,875
+665,387
| +30% | +$7.08M | 0.06% | 366 |
|
|
2019
Q3 | $23.9M | Buy |
2,200,488
+407,935
| +23% | +$4.44M | 0.05% | 463 |
|
|
2019
Q2 | $16.8M | Buy |
1,792,553
+1,578,723
| +738% | +$15.9M | 0.03% | 631 |
|
|
2019
Q1 | $2.63M | Buy |
+213,830
| New | +$2.61M | ﹤0.01% | 1574 |
|
|
2018
Q4 | – | Sell |
-16,500
| Closed | -$237K | – | 2986 |
|
|
2018
Q3 | $237K | Sell |
16,500
-322,241
| -95% | -$4.46M | ﹤0.01% | 2613 |
|
|
2018
Q2 | $5.05M | Sell |
338,741
-464,029
| -58% | -$6.45M | 0.01% | 1276 |
|
|
2018
Q1 | $10.5M | Buy |
802,770
+420,108
| +110% | +$5.52M | 0.02% | 954 |
|
|
2017
Q4 | $4.63M | Buy |
382,662
+173,055
| +83% | +$2.19M | 0.01% | 1386 |
|
|
2017
Q3 | $2.71M | Buy |
209,607
+26,767
| +15% | +$353K | ﹤0.01% | 1604 |
|
|
2017
Q2 | $2.71M | Buy |
182,840
+26,794
| +17% | +$373K | ﹤0.01% | 1561 |
|
|
2017
Q1 | $1.87M | Buy |
156,046
+5,538
| +4% | +$70.1K | ﹤0.01% | 1788 |
|
|
2016
Q4 | $2.1M | Buy |
+150,508
| New | +$2.09M | ﹤0.01% | 1771 |
|
Other funds holding LFCR
WC
LPAM
GRIM
3C
QOP
Russell Investments Group's LFCR Position: Q2 2026 in Review
Russell Investments Group increased its Lifecore Biomedical (LFCR) stake by 62% in Q2 2026, buying an estimated $21.6K and bringing the position to 11,199 shares worth $58.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3586.
Russell Investments Group first reported a position in LFCR in Q4 2016 and has held it in 31 quarters since. The position peaked at $32.4M in Q4 2019. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.
- Russell Investments Group held 11,199 shares of Lifecore Biomedical worth $58.8K as of Q2 2026.
- Russell Investments Group bought 4,293 Lifecore Biomedical shares in Q2 2026, an estimated $21.6K.
- Lifecore Biomedical made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3586 holding.
- Russell Investments Group first reported a position in Lifecore Biomedical in Q4 2016 and has held it in 31 quarters since.
- Russell Investments Group's Lifecore Biomedical position peaked at $32.4M in Q4 2019.
- 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.
Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.